People · Operator

Joseph Sardano

Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology

1
Companies
2
Filings
$6.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
BirchBioMed Inc.BiotechnologySeries A$6.5M$571K2025
Operator network

Joseph Sardano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mark Miller · 18 companies · 1 sharedMark MillerHerve Girsault · 2 companies · 1 sharedHerve GirsaultJOSEPH C. SARDANO · 2 companies · 1 sharedJOSEPH C. SARDANORichard J. Shaw · 2 companies · 1 sharedRichard J. ShawTeresa Bair · 2 companies · 1 sharedTeresa BairCarlos Camozzi · 1 companies · 1 sharedCarlos CamozziCharles Ellis · 1 companies · 1 sharedCharles EllisCharles N. Ellis · 1 companies · 1 sharedCharles N. EllisJohn Verbeck · 1 companies · 1 sharedJohn VerbeckJon M. Verbeck · 1 companies · 1 sharedJon M. VerbeckMark S. Miller · 1 companies · 1 sharedMark S. MillerRyan V. Hartwell · 1 companies · 1 sharedRyan V. HartwellSusan Elliott · 1 companies · 1 sharedSusan ElliottSusan M. Elliott · 1 companies · 1 sharedSusan M. ElliottTeresa S. Bair · 1 companies · 1 sharedTeresa S. BairBirchBioMed Inc. · $6.5M raisedBirchBioMed Inc.Joseph SardanoJS
Joseph Sardano Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Joseph Sardano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Mark Miller118
JOSEPH C. SARDANO12
Richard J. Shaw12
Teresa Bair12
Herve Girsault12
Jon M. Verbeck11
John Verbeck11
Charles N. Ellis11
Teresa S. Bair11
Charles Ellis11
Carlos Camozzi11
Susan Elliott11
Susan M. Elliott11
Ryan V. Hartwell11
Mark S. Miller11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.